Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02558751 · ClinicalTrials.gov registry record · Early Phase 1
Pneumonia Vaccine in Aging HIV Positive Individuals
A Early Phase 1 study, sponsored by University of Toledo Health Science Campus.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 51
- Enrollment target
NCT02558751 is a Early Phase 1 study that has completed, run by University of Toledo Health Science Campus. The registered enrollment target is 51 participants.
The verdict
NCT02558751, a Early Phase 1 study, has completed, sponsored by University of Toledo Health Science Campus.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
The investigators hypothesized that vaccination with either the 23-valent pneumococcal polysaccharide vaccine (PPV23) alone or the 13-valent pneumococcal conjugate vaccine (PCV 13) followed by PPV23 results in similar antibody levels/functional activity and induce a similar pneumococcal polysaccharide (PPS)-specific B cell response in HIV-positive individuals \>50 years of age and HIV-negative persons\>50 years of age. The investigators immunized the study group HIV+ persons\>50 and controls (HIV negative \>50 years) with PCV13 followed by PPV23 and HIV+\>50 with PPV23 alone. The investigators examined immune responses to PPS23F and PPS14 on a quantitative and qualitative level using ELISA and opsonophagocytic assays (OPA). To test the hypothesis that the levels of antigen specific B cells identified with PPS were comparable between the PPV23 and PCV13 vaccine recipients. Pre- and post-immunization peripheral blood samples were obtained. Extensive B cell phenotype analysis using fluorescent antibodies was used to characterize PPS-labeled B cells. Specific phenotypes were correlated with antibody levels and OPA and compared to historic populations immunized with PPV.
Interventions
- BIOLOGICAL 23-valent pneumococcal polysaccharide vaccine
- BIOLOGICAL 13-valent pneumococcal conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02558751
The ClinicalTrials.gov registry entry for NCT02558751 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Toledo Health Science Campus, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 23-valent pneumococcal polysaccharide vaccine is the first listed.
NCT02558751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02558751 about?
NCT02558751 is a clinical study titled "Pneumonia Vaccine in Aging HIV Positive Individuals". The investigators hypothesized that vaccination with either the 23-valent pneumococcal polysaccharide vaccine (PPV23) alone or the 13-valent pneumococcal conjugate vaccine (PCV 13) followed by PPV23 results in similar antibody levels/functional activity and induce a similar pneumococcal polysacchari...
What is the current status of trial NCT02558751?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 51 participants. The study started on 2013-07. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02558751?
The interventions under investigation include: 23-valent pneumococcal polysaccharide vaccine (BIOLOGICAL), 13-valent pneumococcal conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02558751?
This trial is sponsored by University of Toledo Health Science Campus, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.